Page 8 - Read Online

GENERAL INFORMATION

About the Journal
Cancer Drug Resistance (CDR), ISSN 2578-532X (Online), is a peer-reviewed, open-access international journal available at www.
oaepublish.com/cdr. The journal focuses on advancing research on the pharmacological and molecular aspects of drug resistance in
cancer and its reversal. It publishes a diverse range of content, including research articles, reviews, commentaries, and perspectives,
with coverage extending to:
● Drug design, delivery, distribution, and cellular drug resistance.
● Molecular mechanisms such as influx/efflux pumps (e.g., ABC pumps), cellular signaling pathways, drug metabolism, target modifications,
and DNA repair.
● Drug classes including DNA-targeted drugs, antihormones, antibodies, and protein kinase inhibitors.
● Both clinical and experimental aspects of cancer drug resistance.

Founded in March 2018 with Professor Godefridus J. Peters as Editor-in-Chief, CDR has rapidly established itself as a prominent journal
in the field. Key milestones include:
● March 2021: Inclusion in Scopus indexing.
● May 2022: Indexing in PubMed Central® (PMC).
● 2023 Highlights: Achieved its first Impact Factor of 3.7 (Journal Citation Report, June 2023).
● 2024 Highlights:
○ June 2024: Impact Factor increased to 4.6, ranking in the Top Quartile (Q1) in the “Oncology” category.
○ June 2024: CiteScore rose to 6.6, achieving a Top Quartile (Q1) position in “Pharmacology (medical)”.

These accomplishments underscore CDR’s commitment to advancing cancer research and reflect its growing global influence.

Information for Authors
Authors are encouraged to prepare manuscripts following the journal’s Author Instructions. Submissions must be made through the
online system at www.oaemesas.com/cdr.

Copyright and Open Access Policy
All articles published in CDR are protected under international copyright laws. Under the Creative Commons Attribution 4.0 International
License, users are granted:
● Free, irrevocable, and worldwide access to the content.
● Rights to copy, use, distribute, perform, display, and create derivative works for any reasonable purpose, with proper attribution to
authorship.
● Rights to make limited printed copies for personal use.
Copyright is reserved by © The Author(s) 2024.

Disclaimer
The information and opinions presented in the journal reflect the views of the authors and not of the journal or its Editorial Board or the
Publisher. Publication does not constitute endorsement by the journal. Neither the CDR nor its publishers nor anyone else involved in
creating, producing or delivering the CDR or the materials contained therein, assumes any liability or responsibility for the accuracy,
completeness, or usefulness of any information provided in the CDR, nor shall they be liable for any direct, indirect, incidental, special,
consequential or punitive damages arising out of the use of the CDR. The CDR, nor its publishers, nor any other party involved in the
preparation of material contained in the CDR represents or warrants that the information contained herein is in every respect accurate
or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such material. Readers
are encouraged to confirm the information contained herein with other sources.

Published by Contacts
OAE Publishing Inc. E-mail: editorial@cdrjournal.com
245 E Main Street Ste 107, Alhambra, CA 91801, USA Website: https://www.oaepublish.com/cdr
Website: www.oaepublish.com
Cancer Drug Resistance V I